Form 4: Johnson & Johnson Executive Exercises Stock Options Nearing Expiration

Kathryn E. Wengel, EVP, Chief TO and Risk Officer of Johnson & Johnson, exercised stock options and sold shares to cover the exercise price and taxes.

Summary

• Kathryn E. Wengel, an executive at Johnson & Johnson, executed transactions involving company stock on February 7, 2025.
• She exercised employee stock options to acquire 32,762 shares of common stock at a price of $100.06 per share.
• Simultaneously, 26,076 shares were withheld to cover the exercise price and associated taxes at a price of $153.12.
• Following these transactions, Wengel directly owns 88,951.8735 shares of Johnson & Johnson common stock.
• She also indirectly owns 281 shares through the ESOP and 75 shares through a 401k plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and can be scrutinized by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The exercise of stock options and subsequent sale of shares to cover taxes is a common practice among executives at publicly traded companies.
• Comparing Wengel's transactions to those of executives at peer companies like Pfizer (PFE) or Merck (MRK) would provide a broader context for assessing the magnitude and timing of these transactions.

Key Dates

Keywords

Form 4, JNJ, Johnson & Johnson, Stock Options, Executive Compensation, Beneficial Ownership, Kathryn E. Wengel